Chauvat A et al J Immunol Methods 2012, Chauvat A et al Hum Vaccin Immunother 2013

• Monitoring of various cancer vaccines based on dendritic cells (Bercovici N et al J Immunother 2008) or recombinant virus (Oudard S et al Cancer Immunol Immunother 2011).
• Identification of peptides derived from tumor antigens (survivin, telomerase, midkine) eliciting natural immune response in cancer patients (Wang XF et al J Immunol 2008, Kerzhero J et al J Immunol 2010, Dosset M et al  Clin Cancer Res 2012, Godet Y et al Clin Cancer Res 2012)
• Preclinical development of mucosal vaccines (Sandoval F et al Sci Transl Med 2013) and strategies to deplete regulatory T cells (Pere H et al Blood 2011)
• Monitoring regulatory T cells and check point inhibitor (PD-1) as prognosis markers and for the prediction of clinical response to anti-angiogenic molecules (Badoual C et al J Clin Oncol 2009, Adotevi O et al J Immunother 2010, Tartour E et al  Cancer Metast Rev 2011, Terme M et al  Cancer Res 2013, Badoual C et al  Cancer Res 2013, Zitvogel L et al Oncoimmunol 2013).